200 related articles for article (PubMed ID: 11255666)
1. The p53 tumour suppressor protein.
Hickman ES; Helin K
Biotechnol Genet Eng Rev; 2000; 17():179-211. PubMed ID: 11255666
[No Abstract] [Full Text] [Related]
2. To pop or not to pop: p53 as a critical modulator of tumour responsiveness to therapy in vivo?
Workman P
Hum Exp Toxicol; 1995 Feb; 14(2):222-5. PubMed ID: 7779451
[No Abstract] [Full Text] [Related]
3. Activation and activities of the p53 tumour suppressor protein.
Bálint E E; Vousden KH
Br J Cancer; 2001 Dec; 85(12):1813-23. PubMed ID: 11747320
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in p53 research and cancer treatment.
Suzuki K; Matsubara H
J Biomed Biotechnol; 2011; 2011():978312. PubMed ID: 21765642
[TBL] [Abstract][Full Text] [Related]
5. Cell cycle control and cancer.
Sherr CJ
Harvey Lect; 2000-2001; 96():73-92. PubMed ID: 12200872
[No Abstract] [Full Text] [Related]
6. Activation of p53 by oncogenes.
Lowe SW
Endocr Relat Cancer; 1999 Mar; 6(1):45-8. PubMed ID: 10732786
[TBL] [Abstract][Full Text] [Related]
7. [TP53 tumor suppressor gene: 20 years (and ten thousand mutations) later].
Hainaut P
Bull Cancer; 2000 Jan; 87(1):11-8. PubMed ID: 10673626
[No Abstract] [Full Text] [Related]
8. DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis.
Canman CE; Chen CY; Lee MH; Kastan MB
Cold Spring Harb Symp Quant Biol; 1994; 59():277-86. PubMed ID: 7587079
[No Abstract] [Full Text] [Related]
9. [The tumor suppressor gene p53 (part one). Structure, function and mechanisms of inactivation].
Martin A
Ann Pathol; 1995; 15(3):178-83. PubMed ID: 7639853
[No Abstract] [Full Text] [Related]
10. Living with p53, dying of p53.
Aylon Y; Oren M
Cell; 2007 Aug; 130(4):597-600. PubMed ID: 17719538
[TBL] [Abstract][Full Text] [Related]
11. p53 mutation heterogeneity in cancer.
Soussi T; Lozano G
Biochem Biophys Res Commun; 2005 Jun; 331(3):834-42. PubMed ID: 15865939
[TBL] [Abstract][Full Text] [Related]
12. Revealing the intricacies of cancer.
Verhagen AM; Lock P
Genome Biol; 2002; 3(6):REPORTS4015. PubMed ID: 12093370
[TBL] [Abstract][Full Text] [Related]
13. Another p53 Doppelgänger?
Kaelin WG
Science; 1998 Jul; 281(5373):57-8. PubMed ID: 9679018
[No Abstract] [Full Text] [Related]
14. Crosstalk between p53 and FOXO transcription factors.
You H; Mak TW
Cell Cycle; 2005 Jan; 4(1):37-8. PubMed ID: 15611669
[TBL] [Abstract][Full Text] [Related]
15. [The ARF-p53 pathway: a line of defence against oncogenic signals].
Larsen CJ
Pathol Biol (Paris); 2000 Apr; 48(3):308-17. PubMed ID: 10858963
[TBL] [Abstract][Full Text] [Related]
16. Novel cancer therapy by reactivation of the p53 apoptosis pathway.
Bykov VJ; Wiman KG
Ann Med; 2003; 35(7):458-65. PubMed ID: 14649328
[TBL] [Abstract][Full Text] [Related]
17. The role of p53 in cell-cycle control and apoptosis: implications for cancer.
Leonard CJ; Canman CE; Kastan MB
Important Adv Oncol; 1995; ():33-42. PubMed ID: 7672812
[No Abstract] [Full Text] [Related]
18. Enforced expression of p14ARF induces p53-dependent cell cycle arrest but not apoptosis.
Gallagher S; Kefford RF; Rizos H
Cell Cycle; 2005 Mar; 4(3):465-72. PubMed ID: 15701968
[TBL] [Abstract][Full Text] [Related]
19. Surfing the p53 network.
Vogelstein B; Lane D; Levine AJ
Nature; 2000 Nov; 408(6810):307-10. PubMed ID: 11099028
[No Abstract] [Full Text] [Related]
20. Tumor-suppressor p53: implications for tumor development and prognosis.
Kirsch DG; Kastan MB
J Clin Oncol; 1998 Sep; 16(9):3158-68. PubMed ID: 9738588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
